Joshua Doyle1, Adham M Khalafallah1, Wuyang Yang1, Yi Sun2, Chetan Bettegowda1, Debraj Mukherjee3. 1. Department of Neurosurgery, Johns Hopkins University School of Medicine, 1800 Orleans Street, Baltimore, MD, 21287, USA. 2. Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 3. Department of Neurosurgery, Johns Hopkins University School of Medicine, 1800 Orleans Street, Baltimore, MD, 21287, USA. dmukher1@jhmi.edu.
Abstract
BACKGROUND: Brainstem high-grade gliomas (HGG) are rare lesions with aggressive behavior that pose significant treatment challenges. The operative use of brainstem safe entry zones has made such lesions surgically accessible, though the benefits of aggressive resection have been unclear. This study aimed to clarify the survival in adult patients. METHODS: We utilized the SEER database (1973-2015) to analyze the association between survival and demographic data, tumor characteristics, and treatment factors in adult patients with brainstem HGGs. Patients without surgical intervention were excluded. Overall survival (OS) was analyzed using univariable and multivariable Cox regression. RESULTS: Our dataset included a total of 502 brainstem HGG patients of which only those who had undergone surgical intervention were included in the analysis, totaling 103. Mean age was 42.4 ± 14.1 years with 57.2% (n = 59) male. Median OS of the entire cohort was 11.0 months. Median OS for patients receiving biopsy, subtotal resection, and gross total resection were 8, 11, and 16 months, respectively. Age, extent of resection, and radiation therapy were selected into the multivariable model. A significant decrease in survival was seen in older patients, 50-60 years (HR = 2.77, p = 0.002) and ≥ 60 years (HR = 5.30, p < 0.001), compared to younger patients (18-30 years). Partial resection (HR = 0.32, p = 0.006) and GTR (HR = 0.24, p < 0.001) sustained survival benefits compared to patients with biopsy only. Patients receiving postoperative radiation demonstrated no survival benefit (HR = 1.57, p = 0.161) in multivariable regression. CONCLUSIONS: While survival of brainstem HGG patients remains poor, for surgically accessible HGGs, STR and GTR were associated with a three and fourfold increase in overall survival when compared to biopsy only.
BACKGROUND: Brainstem high-grade gliomas (HGG) are rare lesions with aggressive behavior that pose significant treatment challenges. The operative use of brainstem safe entry zones has made such lesions surgically accessible, though the benefits of aggressive resection have been unclear. This study aimed to clarify the survival in adult patients. METHODS: We utilized the SEER database (1973-2015) to analyze the association between survival and demographic data, tumor characteristics, and treatment factors in adult patients with brainstem HGGs. Patients without surgical intervention were excluded. Overall survival (OS) was analyzed using univariable and multivariable Cox regression. RESULTS: Our dataset included a total of 502 brainstem HGG patients of which only those who had undergone surgical intervention were included in the analysis, totaling 103. Mean age was 42.4 ± 14.1 years with 57.2% (n = 59) male. Median OS of the entire cohort was 11.0 months. Median OS for patients receiving biopsy, subtotal resection, and gross total resection were 8, 11, and 16 months, respectively. Age, extent of resection, and radiation therapy were selected into the multivariable model. A significant decrease in survival was seen in older patients, 50-60 years (HR = 2.77, p = 0.002) and ≥ 60 years (HR = 5.30, p < 0.001), compared to younger patients (18-30 years). Partial resection (HR = 0.32, p = 0.006) and GTR (HR = 0.24, p < 0.001) sustained survival benefits compared to patients with biopsy only. Patients receiving postoperative radiation demonstrated no survival benefit (HR = 1.57, p = 0.161) in multivariable regression. CONCLUSIONS: While survival of brainstem HGG patients remains poor, for surgically accessible HGGs, STR and GTR were associated with a three and fourfold increase in overall survival when compared to biopsy only.
Authors: Debraj Mukherjee; Veysel Antar; Burcak Soylemez; Ulas Cikla; Bora Gürer; Mehmet A Ekici; Aaron S Field; M Shahriar Salamat; Mustafa K Başkaya Journal: Neurosurg Rev Date: 2018-08-22 Impact factor: 3.042
Authors: P G Fisher; S N Breiter; B S Carson; M D Wharam; J A Williams; J D Weingart; D R Foer; P T Goldthwaite; T Tihan; P C Burger Journal: Cancer Date: 2000-10-01 Impact factor: 6.860
Authors: J S Guillamo; A Monjour; L Taillandier; B Devaux; P Varlet; C Haie-Meder; G L Defer; P Maison; J J Mazeron; P Cornu; J Y Delattre Journal: Brain Date: 2001-12 Impact factor: 13.501
Authors: Maryam Rahman; Joseph Abbatematteo; Edward K De Leo; Paul S Kubilis; Sasha Vaziri; Frank Bova; Elias Sayour; Duane Mitchell; Alfredo Quinones-Hinojosa Journal: J Neurosurg Date: 2016-09-30 Impact factor: 5.115
Authors: Hoon Kim; Siyuan Zheng; Seyed S Amini; Selene M Virk; Tom Mikkelsen; Daniel J Brat; Jonna Grimsby; Carrie Sougnez; Florian Muller; Jian Hu; Andrew E Sloan; Mark L Cohen; Erwin G Van Meir; Lisa Scarpace; Peter W Laird; John N Weinstein; Eric S Lander; Stacey Gabriel; Gad Getz; Matthew Meyerson; Lynda Chin; Jill S Barnholtz-Sloan; Roel G W Verhaak Journal: Genome Res Date: 2015-02-03 Impact factor: 9.043